Dr. Maria Martinez -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Maria Martinez, a Oncology physician based in City, IN. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Maria Martinez has received $141,511.20 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Maria Martinez
- Medical Specialty: Oncology
- Practice Location: City, IN, Indiana
- NPI Number: 1105849181
- Payment Records Span: 2025-06-21 to 2025-06-21
Payment Summary
Dr. Maria Martinez has received a total of $141,511.20 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $141,511.20 per transaction.
- Total Payments Received: $141,511.20
- Number of Transactions: 1
- Average Payment: $141,511.20
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Maria Martinez's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Ownership Interest | $141,511.20 | Ownership stakes, dividends, and investment returns |
The largest payment category for Dr. Maria Martinez is Ownership Interest, accounting for 100% ($141,511.20) of total pharmaceutical payments received. This indicates a financial ownership interest in a pharmaceutical or medical device company.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Maria Martinez. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Gilead Sciences | $141,511.20 | 1 |
Dr. Maria Martinez has a financial relationship with Gilead Sciences, receiving $141,511.20 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Maria Martinez. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Trikafta -- Referenced in payment records from pharmaceutical companies to Dr. Maria Martinez
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
Patient Guidance: Questions to Ask About Pharma Payments
If Dr. Maria Martinez is your physician and you have questions about their pharmaceutical industry payments, here are some constructive approaches:
- "I saw you received payments from pharmaceutical companies. Can you help me understand those relationships?" -- Most physicians are happy to discuss these relationships transparently. Payments often fund legitimate medical education, research, and advisory work.
- "Are there alternative treatments you would recommend if cost were not a factor?" -- This question helps ensure prescribing decisions are based on clinical evidence rather than any single factor.
- "Is there a generic option available for any medications you prescribe?" -- Understanding all available options, including generics, ensures you can make an informed choice about your treatment plan.
- "Can you tell me more about Trikafta and why it is the best option for me?" -- Since this product appears in Dr. Maria Martinez's payment records, understanding the clinical rationale for its use is especially important.
Remember, pharmaceutical payments do not inherently indicate wrongdoing. Many payments support valuable activities like medical research, professional education, and clinical trial oversight. However, transparency empowers patients to have informed conversations with their healthcare providers.
Understanding Oncology Pharmaceutical Payments
Pharmaceutical payment patterns vary significantly by medical specialty. Oncology is a specialty where pharmaceutical companies frequently engage physicians for consulting, speaking, and research activities related to the treatments and devices used in this field.
When evaluating Dr. Maria Martinez's payment profile, it is important to compare against other Oncology physicians rather than doctors in unrelated fields. Specialists who work with expensive drugs, medical devices, or cutting-edge treatments typically receive higher payment volumes than primary care physicians, which reflects the nature of the specialty rather than any impropriety.
Geographic context also matters. Payment patterns in Indiana may differ from national averages due to local healthcare market dynamics, presence of academic medical centers, and the concentration of pharmaceutical company headquarters in the region.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Maria Martinez in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Gilead Sciences | $141,511.20 | ownership | Trikafta | 2025-06-21 | Not Assessed |
Frequently Asked Questions About Dr. Maria Martinez's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much has Dr. Maria Martinez received from pharmaceutical companies?
According to CMS Open Payments data, Dr. Maria Martinez has received a total of $141,511.20 in pharmaceutical industry payments across 1 recorded transactions. These payments came from 1 pharmaceutical companies.
What types of payments has Dr. Maria Martinez received?
Dr. Maria Martinez's payments include Ownership Interest ($141,511.20). Each payment type reflects a different kind of professional engagement with pharmaceutical companies.
Does receiving pharmaceutical payments mean Dr. Maria Martinez is compromised?
No. Receiving pharmaceutical payments does not inherently indicate wrongdoing or compromised medical judgment. Many payments support legitimate professional activities such as medical research, clinical trial oversight, continuing education, and advisory board participation. The Sunshine Act requires disclosure of these payments precisely so that patients can have transparent, informed discussions with their physicians about these financial relationships.
What is the NPI number 1105849181 for Dr. Maria Martinez?
NPI stands for National Provider Identifier. It is a unique 10-digit identification number issued by CMS (Centers for Medicare and Medicaid Services) to healthcare providers in the United States. Dr. Maria Martinez's NPI number 1105849181 uniquely identifies them across all CMS databases, including the Open Payments system that tracks pharmaceutical industry payments to physicians.
How can I verify Dr. Maria Martinez's pharmaceutical payment data?
All payment data shown on DoctorPharmaData comes from the official CMS Open Payments database, which is publicly available at openpaymentsdata.cms.gov. You can search for Dr. Maria Martinez using their NPI number (1105849181) to verify all payment records directly with the federal government's database. The data is updated annually with each new reporting cycle.
What is Oncology and how do pharma payments work in this field?
Oncology is a medical specialty practiced by Dr. Maria Martinez in City, IN. Pharmaceutical payments in oncology typically relate to the drugs, devices, and treatments used in this field. Companies may pay oncology specialists for consulting on drug development, speaking about treatments at medical conferences, conducting clinical research, or participating on scientific advisory boards.
Understanding This Doctor Payment Report
This transparency report for Dr. Maria Martinez is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Oncology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Maria Martinez's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Maria Martinez and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Oncology Specialty Payment Data -- See payment patterns for all oncology physicians
- Indiana Physician Payments -- Browse pharmaceutical payments to physicians in Indiana
- Oncology Physicians in Indiana -- Compare Dr. Maria Martinez to peers in the same state and specialty
- Gilead Sciences Payment Profile -- View all payments made by Dr. Maria Martinez's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Maria Martinez's NPI (1105849181) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.